Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28526538

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Jun
First author
Krop IE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):696-697. doi: 10.1016/S1470-2045(17)30303-0.
    note
    Source null
    related pmid
    28526537
    relationship
    Comment in

Authors and identifiers

  1. name
    Krop IE
    type
    Author
  2. name
    Kim SB
    type
    Author
  3. name
    Martin AG
    type
    Author
  4. name
    LoRusso PM
    type
    Author
  5. name
    Ferrero JM
    type
    Author
  6. name
    Badovinac-Crnjevic T
    type
    Author
  7. name
    Hoersch S
    type
    Author
  8. name
    Smitt M
    type
    Author
  9. name
    Wildiers H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Krop IE
    type
    Author
  2. name
    Kim SB
    type
    Author
  3. name
    Martin AG
    type
    Author
  4. name
    LoRusso PM
    type
    Author
  5. name
    Ferrero JM
    type
    Author
  6. name
    Badovinac-Crnjevic T
    type
    Author
  7. name
    Hoersch S
    type
    Author
  8. name
    Smitt M
    type
    Author
  9. name
    Wildiers H
    type
    Author
bibliography ids
  1. nci-bib-8fe3b92a9513b9f97848db20
book metadata
content sha256
4b3ebb57d40b04a7d0ecde4e706da28322052188c1bb36354c315d4dbec214d8
document type
citation
dois
  1. 10.1016/S1470-2045(17)30313-3
electronic publication date
display
2017 May 16
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28526538
immutable id
pubmed:28526538@4b3ebb57d40b04a7d0ecde4e706da28322052188c1bb36354c315d4dbec214d8
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
743-754
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):696-697. doi: 10.1016/S1470-2045(17)30303-0.
    note
    Source null
    related pmid
    28526537
    relationship
    Comment in
outcomes validated
false
pmid
28526538
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
61ccfc06035a0f9a129772220d22690cf0c69476c0f6f4fe2c38122478f2b023
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jun
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28526538/
title
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

Preserved source evidence · Not medical advice